DDInter704 DDInter1147
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Meningococcal group C polysaccharide is group-specific polysaccharide antigens extracted and purified from *Neisseria meningitidis* serogroup C. *N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia. It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup C.
Everolimus {u} (Compound) resembles {v} (Compound) Pimecrolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Everolimus {u} (Compound) treats {v} (Disease) kidney cancer
Everolimus {u} (Compound) binds {v} (Gene) FKBP1A
Everolimus {u} (Compound) upregulates {v} (Gene) USP20
Everolimus {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2D6 Inhibitors
Everolimus {u} (Compound) downregulates {v} (Gene) ATF1
Everolimus {u} (Compound) causes {v} (Side Effect) Pericardial effusion
Everolimus (Compound) resembles Pimecrolimus (Compound)
Everolimus (Compound) resembles Temsirolimus (Compound)
Everolimus (Compound) treats kidney cancer (Disease)
Everolimus (Compound) binds FKBP1A (Gene)
Everolimus (Compound) upregulates USP20 (Gene)
Everolimus (Compound) is included by Cytochrome P450 2D6 Inhibitors (Pharmacologic Class)
Everolimus (Compound) downregulates ATF1 (Gene)
Everolimus (Compound) causes Pericardial effusion (Side Effect)